We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00173095
Recruitment Status : Unknown
Verified January 2005 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : September 15, 2005
Last Update Posted : September 15, 2005
Sponsor:
Information provided by:

Study Description
Brief Summary:
According to Morgan et. al. (J Neurosurg 101:1026-1029, 2004): bilirubin as a cerebrospinal fluid marker of sentinel subarachnoid hemorrhage: a preliminary report in pigs, we're going to test the hypothesis in the cerebrospinal fluid of spontaneous subarachnoid hemorrhage patients.

Condition or disease
Spontaneous Subarachnoid Hemorrhage

Detailed Description:
According to Morgan et. al. (J Neurosurg 101:1026-1029, 2004): bilirubin as a cerebrospinal fluid marker of sentinel subarachnoid hemorrhage: a preliminary report in pigs, we're going to test the hypothesis in the cerebrospinal fluid of spontaneous subarachnoid hemorrhage patients. We'll collect the serial cerebrospinal fluid in 15-20 spontaneous subarachnoid hemorrhage patients to see the time sequence of changes in bilirubin levels.

Study Design

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients
Study Start Date : January 2005
Estimated Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • spontaneous subarachnoid hemorrhage in less than three days

Exclusion Criteria:

  • spontaneous subarachnoid hemorrhage more than three days
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00173095


Contacts
Contact: Chang-Mu Chen, MD 886-2-23123456 ext 5324 cmchen10@ms27.hinet.net

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Chang-Mu Chen, M.D.    886-2-23123456 ext 5324    cmchen10@ms27.hinet.net   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Cheng-Mu Chen, M.D. National Taiwan University Hospital
More Information

ClinicalTrials.gov Identifier: NCT00173095     History of Changes
Other Study ID Numbers: 9461700413
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: September 15, 2005
Last Verified: January 2005

Additional relevant MeSH terms:
Hemorrhage
Subarachnoid Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Bilirubin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs